Anelisa K Coutinho, Yazmin Carolina Blanco Vazquez, Markus Andret Cavalcante Gifoni, Angela Marie Jansen, Juan Manuel O'Connor, Juan Carlos Samamé Pérez-Vargas, Mariana Rico-Restrepo, Gayatri Sanku, Guillermo Mendez
{"title":"拉丁美洲BRAF-V600E转移性结直肠癌管理的现状：拉丁美洲专家小组的建议。","authors":"Anelisa K Coutinho, Yazmin Carolina Blanco Vazquez, Markus Andret Cavalcante Gifoni, Angela Marie Jansen, Juan Manuel O'Connor, Juan Carlos Samamé Pérez-Vargas, Mariana Rico-Restrepo, Gayatri Sanku, Guillermo Mendez","doi":"10.3332/ecancer.2024.1807","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer is the second leading cause of cancer death in Latin America (LA) with a projected 65.4% increase by 2040. Up to 10% of metastatic CRC (mCRC) patients in LA had an activating BRAF mutation. In clinical trials, targeted therapies for BRAF-V600E mutated mCRC have improved patient outcomes. However, in LA, BRAF-V600E testing and treatment of positive patients remains variable. To address this need, the Americas Health Foundation convened a meeting of LA experts on <i>BRAF-V600E</i> mCRC to develop treatment recommendations. The expert panel addressed the current landscape of BRAF-V600E mCRC testing, diagnosis and treatment in the region and identified significant limitations. Local guidelines, multidisciplinary boards, and tumor genotyping are among the recommendations. The panel also made first-line, second-line and surgery recommendations for patients after diagnosis.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1807"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959131/pdf/","citationCount":"0","resultStr":"{\"title\":\"Current landscape of BRAF-V600E metastatic CRC management in Latin America: an expert Latin American panel's recommendations.\",\"authors\":\"Anelisa K Coutinho, Yazmin Carolina Blanco Vazquez, Markus Andret Cavalcante Gifoni, Angela Marie Jansen, Juan Manuel O'Connor, Juan Carlos Samamé Pérez-Vargas, Mariana Rico-Restrepo, Gayatri Sanku, Guillermo Mendez\",\"doi\":\"10.3332/ecancer.2024.1807\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Colorectal cancer is the second leading cause of cancer death in Latin America (LA) with a projected 65.4% increase by 2040. Up to 10% of metastatic CRC (mCRC) patients in LA had an activating BRAF mutation. In clinical trials, targeted therapies for BRAF-V600E mutated mCRC have improved patient outcomes. However, in LA, BRAF-V600E testing and treatment of positive patients remains variable. To address this need, the Americas Health Foundation convened a meeting of LA experts on <i>BRAF-V600E</i> mCRC to develop treatment recommendations. The expert panel addressed the current landscape of BRAF-V600E mCRC testing, diagnosis and treatment in the region and identified significant limitations. Local guidelines, multidisciplinary boards, and tumor genotyping are among the recommendations. The panel also made first-line, second-line and surgery recommendations for patients after diagnosis.</p>\",\"PeriodicalId\":11460,\"journal\":{\"name\":\"ecancermedicalscience\",\"volume\":\"18 \",\"pages\":\"1807\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959131/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ecancermedicalscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3332/ecancer.2024.1807\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2024.1807","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Current landscape of BRAF-V600E metastatic CRC management in Latin America: an expert Latin American panel's recommendations.
Colorectal cancer is the second leading cause of cancer death in Latin America (LA) with a projected 65.4% increase by 2040. Up to 10% of metastatic CRC (mCRC) patients in LA had an activating BRAF mutation. In clinical trials, targeted therapies for BRAF-V600E mutated mCRC have improved patient outcomes. However, in LA, BRAF-V600E testing and treatment of positive patients remains variable. To address this need, the Americas Health Foundation convened a meeting of LA experts on BRAF-V600E mCRC to develop treatment recommendations. The expert panel addressed the current landscape of BRAF-V600E mCRC testing, diagnosis and treatment in the region and identified significant limitations. Local guidelines, multidisciplinary boards, and tumor genotyping are among the recommendations. The panel also made first-line, second-line and surgery recommendations for patients after diagnosis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
